Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Chronic Graft-Versus-Host Disease

Author(s): Javier Bolanos-Meade and Georgia B. Vogelsang

Volume 14, Issue 20, 2008

Page: [1974 - 1986] Pages: 13

DOI: 10.2174/138161208785061373

Price: $65

Abstract

Chronic graft-versus-host disease is the most common late, non-relapse complication of transplantation yet it is also one of the least studied. It is the primary cause of morbidity and mortality of long-term survivors of allogeneic bone marrow transplants. Like acute graft-versus-host disease, it does have a strong antitumor effect. The recent National Institutes of Health sponsored Chronic Graft-versus- Host Disease Consensus Conference has proposed new criteria for diagnosis and staging, pathology, biomarkers, response and supportive care. New understanding of the pathophysiology of chronic graft-versus-host disease (i.e. the role of B cells) is already having an impact on therapy. Novel agents such as pentostatin, mycophenolate mofetil, rituximab, extracorporeal photochemotherapy, etc. are improving the outcome of steroid refractory chronic graft-versus-host disease.

Keywords: Host Disease, Chronic graft, antitumor effect, pathology, Novel agents, pentostatin, mycophenolate mofetil, extracorporeal photochemotherapy, rituximab


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy